Emerging studies have suggested that targeting secreted-oncogenic proteins may reverse tumor immune evasion, and our study provides the theoretical basis for the development of precision cancer therapies targeting TDE-mediated p53 secretion. The gene discussed is TP53; the disease is cancer.